Question follow-through · 5904
Genomics
To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for his policies of the evidence base that underpins the use of tissue stabilisers - as an alternative to fresh frozen tissue - for whole genome sequ
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 2 Jun 2026
- Target answer date
- 4 Jun 2026
- Answer
- 9 Jun 2026 · 7 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
2 Jun 2026
Question tabled
To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for his policies of the evidence base that underpins the use of tissue stabilisers - as an alternative to fresh frozen tissue - for whole genome sequ
4 Jun 2026
Target answer date
Date supplied by the official written-questions record.
9 Jun 2026
Answer published
NHS England has produced national sample handling guidance, including for whole genome sequencing (WGS), of solid tumours to standardise the collection, processing, and transport of tumour samples, helping to maintain DNA quality and support access to pre...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
No later same-department questions indexed.
This is an absence in covered public data, not evidence that no follow-up occurred elsewhere.